511 related articles for article (PubMed ID: 30707660)
1. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.
Edeline J; Benabdelghani M; Bertaut A; Watelet J; Hammel P; Joly JP; Boudjema K; Fartoux L; Bouhier-Leporrier K; Jouve JL; Faroux R; Guerin-Meyer V; Kurtz JE; Assénat E; Seitz JF; Baumgaertner I; Tougeron D; de la Fouchardière C; Lombard-Bohas C; Boucher E; Stanbury T; Louvet C; Malka D; Phelip JM
J Clin Oncol; 2019 Mar; 37(8):658-667. PubMed ID: 30707660
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
Kim ST; Kang JH; Lee J; Lee HW; Oh SY; Jang JS; Lee MA; Sohn BS; Yoon SY; Choi HJ; Hong JH; Kim MJ; Kim S; Park YS; Park JO; Lim HY
Ann Oncol; 2019 May; 30(5):788-795. PubMed ID: 30785198
[TBL] [Abstract][Full Text] [Related]
3. Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.
Phelip JM; Desrame J; Edeline J; Barbier E; Terrebonne E; Michel P; Perrier H; Dahan L; Bourgeois V; Akouz FK; Soularue E; Ly VL; Molin Y; Lecomte T; Ghiringhelli F; Coriat R; Louafi S; Neuzillet C; Manfredi S; Malka D;
J Clin Oncol; 2022 Jan; 40(3):262-271. PubMed ID: 34662180
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
[TBL] [Abstract][Full Text] [Related]
5. Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies.
Edeline J; Hirano S; Bertaut A; Konishi M; Benabdelghani M; Uesaka K; Watelet J; Ohtsuka M; Hammel P; Kaneoka Y; Joly JP; Yamamoto M; Monard L; Ambo Y; Louvet C; Ando M; Malka D; Nagino M; Phelip JM; Ebata T
Eur J Cancer; 2022 Mar; 164():80-87. PubMed ID: 35182925
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
7. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
[TBL] [Abstract][Full Text] [Related]
8. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.
Chen JS; Hsu C; Chiang NJ; Tsai CS; Tsou HH; Huang SF; Bai LY; Chang IC; Shiah HS; Ho CL; Yen CJ; Lee KD; Chiu CF; Rau KM; Yu MS; Yang Y; Hsieh RK; Chang JY; Shan YS; Chao Y; Chen LT;
Ann Oncol; 2015 May; 26(5):943-949. PubMed ID: 25632066
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
Primrose JN; Fox RP; Palmer DH; Malik HZ; Prasad R; Mirza D; Anthony A; Corrie P; Falk S; Finch-Jones M; Wasan H; Ross P; Wall L; Wadsley J; Evans JTR; Stocken D; Praseedom R; Ma YT; Davidson B; Neoptolemos JP; Iveson T; Raftery J; Zhu S; Cunningham D; Garden OJ; Stubbs C; Valle JW; Bridgewater J;
Lancet Oncol; 2019 May; 20(5):663-673. PubMed ID: 30922733
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study.
De La Fouchardière C; Malka D; Cropet C; Chabaud S; Raimbourg J; Botsen D; Launay S; Evesque L; Vienot A; Perrier H; Jary M; Rinaldi Y; Coutzac C; Bachet JB; Neuzillet C; Williet N; Desgrippes R; Grainville T; Aparicio T; Peytier A; Lecomte T; Roth GS; Thirot-Bidault A; Lachaux N; Bouché O; Ghiringhelli F
J Clin Oncol; 2024 Mar; 42(9):1055-1066. PubMed ID: 38232341
[TBL] [Abstract][Full Text] [Related]
11. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
Choi IS; Kim KH; Lee JH; Suh KJ; Kim JW; Park JH; Kim YJ; Kim JS; Kim JH; Kim JW
Eur J Cancer; 2021 Sep; 154():288-295. PubMed ID: 34303267
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA).
Ioka T; Kanai M; Kobayashi S; Sakai D; Eguchi H; Baba H; Seo S; Taketomi A; Takayama T; Yamaue H; Takahashi M; Sho M; Kamei K; Fujimoto J; Toyoda M; Shimizu J; Goto T; Shindo Y; Yoshimura K; Hatano E; Nagano H;
J Hepatobiliary Pancreat Sci; 2023 Jan; 30(1):102-110. PubMed ID: 35900311
[TBL] [Abstract][Full Text] [Related]
13. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C; Okusaka T; Mizusawa J; Katayama H; Ueno M; Ikeda M; Ozaka M; Okano N; Sugimori K; Fukutomi A; Hara H; Mizuno N; Yanagimoto H; Wada K; Tobimatsu K; Yane K; Nakamori S; Yamaguchi H; Asagi A; Yukisawa S; Kojima Y; Kawabe K; Kawamoto Y; Sugimoto R; Iwai T; Nakamura K; Miyakawa H; Yamashita T; Hosokawa A; Ioka T; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Ann Oncol; 2019 Dec; 30(12):1950-1958. PubMed ID: 31566666
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
[TBL] [Abstract][Full Text] [Related]
15. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer.
Kim ST; Jang KT; Lee SJ; Jang HL; Lee J; Park SH; Park YS; Lim HY; Kang WK; Park JO
BMC Cancer; 2015 Jul; 15():530. PubMed ID: 26189560
[TBL] [Abstract][Full Text] [Related]
16. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.
Vogel A; Kasper S; Bitzer M; Block A; Sinn M; Schulze-Bergkamen H; Moehler M; Pfarr N; Endris V; Goeppert B; Merx K; Schnoy E; Siveke JT; Michl P; Waldschmidt D; Kuhlmann J; Geissler M; Kahl C; Evenkamp R; Schmidt T; Kuhlmann A; Weichert W; Kubicka S
Eur J Cancer; 2018 Mar; 92():11-19. PubMed ID: 29413685
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study.
Phelip JM; Vendrely V; Rostain F; Subtil F; Jouve JL; Gasmi M; Michel P; Le Malicot K; Smith D; Seitz JF; Fauchart JP; Martin P; Bennouna J; Morin T; Bonnet I; Maingon P; Lepage C; Chauffert B
Eur J Cancer; 2014 Nov; 50(17):2975-82. PubMed ID: 25241229
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review.
Fiteni F; Nguyen T; Vernerey D; Paillard MJ; Kim S; Demarchi M; Fein F; Borg C; Bonnetain F; Pivot X
Cancer Med; 2014 Dec; 3(6):1502-11. PubMed ID: 25111859
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.
André T; Tournigand C; Rosmorduc O; Provent S; Maindrault-Goebel F; Avenin D; Selle F; Paye F; Hannoun L; Houry S; Gayet B; Lotz JP; de Gramont A; Louvet C;
Ann Oncol; 2004 Sep; 15(9):1339-43. PubMed ID: 15319238
[TBL] [Abstract][Full Text] [Related]
20. A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
Niger M; Nichetti F; Fornaro L; Pircher C; Morano F; Palermo F; Rimassa L; Pressiani T; Berardi R; Gardini AC; Sperti E; Salvatore L; Melisi D; Bergamo F; Siena S; Mosconi S; Longarini R; Arcangeli G; Corallo S; Delliponti L; Tamberi S; Fea E; Brandi G; Rapposelli IG; Salati M; Baili P; Miceli R; Ljevar S; Cavallo I; Sottotetti E; Martinetti A; Busset MDD; Sposito C; Di Bartolomeo M; Pietrantonio F; de Braud F; Mazzaferro V
BMC Cancer; 2024 Apr; 24(1):436. PubMed ID: 38589856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
